Navigation Links
OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
Date:9/22/2011

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will be hosting an exhibition table at the 6th Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec's exhibition will highlight a poster presentation providing preliminary results from their phase IV head and neck cancer and phase I breast cancer trials carried out in Europe using OncoSec's OMS ElectroChemotherapy™ treatment approach.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

"We are pleased to highlight at this important scientific conference the extent of our clinical development activities of our OMS ElectroChemotherapy™ program and begin to share validating data from prior clinical trials that supports the merits of the therapy," said Punit Dhillon, president and CEO of OncoSec. "Our aim is to complete data analysis from the previous OMS ElectroChemotherapy™ programs and present this clinical data at applicable oncology and scientific meetings and seek a commercialization path for the product with the help of one or more industry partnerships from select geographic regions or globally."

Through its asset acquisition, OncoSec has accumulated a significant database of clinical data in a variety of tumor types using the OMS ElectroChemotherapy™ therapeutic approach.  To date OMS ElectroChemotherapy™ has been tested in several clinical trials ranging from Phase I through Phase IV conducted in 13 countries across over 50 sites.  Human data has been collected in over 400 patients with cancers ranging from basal and squamous cell carcinomas, melanoma, adenocarcinoma, Kaposi's sarcoma, pancreatic, hepatic, oral, and head and neck cancers. 

The 6th Fire, Ice, and Beyond: The Future of Ablation Therapies is an advanced program presenting guidance in understanding the expanding field of new and cutting edge energy sources, combination therapies, embolic pharmaceuticals, treatment planning, fusion imaging, and navigation that make up Interventional Oncology procedures. This conference will be attended by physicians, scientists, and business executives in their areas of expertise.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... new report "Global Diagnostic Ultrasound Devices Market Assessment & Forecast: 2015-2019" ... diagnostic ultrasound devices market was valued at US$ 5,381.1 million in ... at a CAGR of 6.8% from 2015 to 2019. The ... for six geographies of North America , ... Latin America , Middle-East and ...
(Date:2/9/2016)... The global prefilled syringes market accounted for $3,905.1 million ... with a CAGR of 12.9% during 2015-2020. Among the ... global prefilled syringes market, with 90.1% share in 2014. ... global market of prefilled syringes is up surging with ... demand for vaccines, increasing prevalence of chronic and lifestyle ...
(Date:2/9/2016)... report "Global Blood Monitoring & Cardiac Monitoring Devices Market Assessment & ... that global market for blood monitoring & cardiac monitoring devices was ... to US$ 24,830.1 million by 2019 at a CAGR of 6.8% ... Europe , Asia-Pacific , ... Africa . The three major factors determining growth ...
Breaking Medicine Technology:
(Date:2/9/2016)... Las Vegas, Nevada (PRWEB) , ... February 09, ... ... is now providing treatment to Medicaid beneficiaries who are diagnosed with autism spectrum ... state of Nevada. Autism treatment using applied behavior analysis (ABA) is key ...
(Date:2/9/2016)... ... February 09, 2016 , ... A ... fee schedule rates and Medicare rates for a variety of medical services in ... Evaluation of the 2015 Fee Schedule Rates in Illinois, are professional ...
(Date:2/9/2016)... York, NY (PRWEB) , ... February 09, 2016 , ... ... the appointment of Dr. David Hung to the company´s Board of Directors. ... a world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO ...
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic ... Teeth whitening is among the most popular cosmetic procedures in dentistry today, but the ... This can put them at risk of teeth whitening-related damage. For a limited time, ...
(Date:2/9/2016)... ... 2016 , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter ... June 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of ... in 2015, the Maui Photo Expedition workshop will once again consist of ...
Breaking Medicine News(10 mins):